Equities
  • Price (MXN)13.50
  • Today's Change0.002 / 0.01%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Mar 26 2021 11:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Alibaba Health Information Technology Ltd grew net income 64.93% from 535.65m to 883.48m despite relatively flat revenues.
Gross margin23.15%
Net profit margin4.26%
Operating margin4.60%
Return on assets5.79%
Return on equity7.69%
Return on investment7.62%
More ▼

Cash flow in CNYView more

In 2024, cash reserves at Alibaba Health Information Technology Ltd fell by 5.75bn. However, the company earned 1.08bn from its operations for a Cash Flow Margin of 4.00%. In addition the company used 4.88bn on investing activities and also paid 1.98bn in financing cash flows.
Cash flow per share0.0883
Price/Cash flow per share45.42
Book value per share1.02
Tangible book value per share0.9476
More ▼

Balance sheet in CNYView more

Alibaba Health Information Technology Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 0.44%.
Current ratio2.45
Quick ratio2.11
Total debt/total equity0.0045
Total debt/total capital0.0044
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.